Article Details

China's Duality Biologics secures $90m in Series B led by Lilly Asia Ventures

Retrieved on: 2021-05-20 04:18:45

Tags for this article:

Click the tags to see associated articles and topics

China's Duality Biologics secures $90m in Series B led by Lilly Asia Ventures. View article details on hiswai:

Excerpt

Hong Kong-listed Chinese biologics technology giant WuXi Biologics's industry investment vehicle, which had participated in DualityBio's Series A ...

Article found on: www.dealstreetasia.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up